Biocryst Pharmaceuticals Inc.

NASDAQ: BCRX    
Share price (5/3/24): $4.48    
Market cap (5/3/24): $924 million
8 Biocryst Pharmaceuticals Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Credit Agreements Filter

EX-10.2
from 10-Q 7 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amendment Number Two to Credit Agreement
12/34/56
EX-10.1
from 10-Q 8 pages This Waiver (This “Waiver”), Dated as of July 14, 2022, Is Entered Into by and Among Biocryst Pharmaceuticals, Inc., a Delaware Corporation (The “Borrower”), the Guarantors Listed on the Signature Pages Hereto (The “Guarantors”), the Lenders Listed on the Signature Pages Hereto (Such Lenders, and the Other Lenders Party to the Credit Agreement (As Defined Below), Together With Their Respective Successors and Permitted Assigns, Each Individually, a “Lender”, and Collectively, the “Lenders”) and Athyrium Opportunities III Co-Invest 1 LP, a Delaware Limited Partnership, as Administrative Agent for the Lenders (In Such Capacity, Together With Its Successors and Assigns in Such Capacity, the “Administrative Agent”), and in Light of the Following
12/34/56
EX-10.101
from 10-K 160 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. in Addition, Certain Personally Identifiable Information Contained in This Document, Marked “[***]” Has Been Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. Amendment Number One to Credit Agreement
12/34/56
EX-10.92
from 10-K 135 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed or Because It Contains Personally Identifiable Information Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. Credit Agreement Dated as of December 7, 2020 Among Biocryst Pharmaceuticals, Inc., as the Borrower, Biocryst Ireland Limited as a Guarantor the Other Guarantors From Time to Time Party Hereto, the Lenders From Time to Time Party Hereto and Athyrium Opportunities III Co-Invest 1 LP, as Administrative Agent
12/34/56
EX-10.7
from 10-Q 9 pages Third Amendment to Second Amended and Restated Credit and Security Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Second Amendment to Second Amended and Restated Credit and Security Agreement
12/34/56
EX-10.1
from 10-Q 9 pages First Amendment to Second Amended and Restated Credit and Security Agreement
12/34/56
EX-10.5
from 10-Q 101 pages Amended and Restated Credit and Security Agreement
12/34/56
EX-10.3
from 10-Q 102 pages Credit and Security Agreement
12/34/56